ENTA - Enanta Pharmaceuticals

-

$undefined

N/A

(N/A)

Enanta Pharmaceuticals NasdaqGS:ENTA Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Location: 4 Kingsbury Avenue, Watertown, MA, 02472, United States | Website: https://www.enanta.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

145.7M

Cash

193.4M

Avg Qtr Burn

-13.87M

Short % of Float

20.60%

Insider Ownership

6.57%

Institutional Own.

87.52%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MAVYRET (Glecaprevir) Details
HCV (Hepatitis C Virus)

Approved

Quarterly sales

Zelicapavir (EDP-938) Details
Viral infection, Respiratory syncytial virus, Respiratory virus

Phase 2

Data readout

EDP-235 Details
Viral infection, COVID-19

Phase 2

Update

Phase 2

Initiation

EDP-323 Details
Viral infection, Respiratory syncytial virus, Respiratory virus

Phase 2a

Update

ENP-297 (FXR inhibitor) Details
Non-alcoholic steatohepatitis

Failed

Discontinued

EDP-305 (FXR Agonist) Details
Non-alcoholic steatohepatitis

Failed

Discontinued